David Stroncek

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Quality assessment of cellular therapies: the emerging role of molecular assays
    David F Stroncek
    Cellular Therapy and Immunogenetics Sections, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA
    Korean J Hematol 45:14-22. 2010
  2. pmc Leukemia cells induce changes in human bone marrow stromal cells
    Sara Civini
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health NIH, Building 10, Room 3C720, 9000 Rockville Pike, Bethesda, MD 20892 1184, USA
    J Transl Med 11:298. 2013
  3. pmc Comparison of endometrial regenerative cells and bone marrow stromal cells
    Huan Wang
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 10:207. 2012
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  5. pmc The stable traits of melanoma genetics: an alternate approach to target discovery
    Tara L Spivey
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 13:156. 2012
  6. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
  7. pmc The establishment of a bank of stored clinical bone marrow stromal cell products
    Marianna Sabatino
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Building 10, Room 1C711, Bethesda, MD 20892 1184, USA
    J Transl Med 10:23. 2012
  8. pmc The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development
    Thomas Ichim
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 9:218. 2011
  9. pmc An immunologic portrait of cancer
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 9:146. 2011
  10. pmc Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy
    Cornelis J M Melief
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    J Transl Med 9:107. 2011

Detail Information

Publications94

  1. pmc Quality assessment of cellular therapies: the emerging role of molecular assays
    David F Stroncek
    Cellular Therapy and Immunogenetics Sections, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA
    Korean J Hematol 45:14-22. 2010
    ..Several examples of the use of gene expression analysis for assessing cellular therapies are presented...
  2. pmc Leukemia cells induce changes in human bone marrow stromal cells
    Sara Civini
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health NIH, Building 10, Room 3C720, 9000 Rockville Pike, Bethesda, MD 20892 1184, USA
    J Transl Med 11:298. 2013
    ..The inflammatory cytokines IFN-γ and TNF-α change the BMSC secretome and we hypothesized that factors produced by tumors or leukemia would also affect the BMSC secretome and investigated the interaction of leukemia cells with BMSCs...
  3. pmc Comparison of endometrial regenerative cells and bone marrow stromal cells
    Huan Wang
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 10:207. 2012
    ..Endometrial regenerative cells (ERC) and bone marrow stromal cells (BMSC) are being used in clinical trials. While they have been reported to have similar characteristics, they have not been directly compared...
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  5. pmc The stable traits of melanoma genetics: an alternate approach to target discovery
    Tara L Spivey
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 13:156. 2012
    ..We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number...
  6. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
    ..In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies...
  7. pmc The establishment of a bank of stored clinical bone marrow stromal cell products
    Marianna Sabatino
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Building 10, Room 1C711, Bethesda, MD 20892 1184, USA
    J Transl Med 10:23. 2012
    ..For many applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment of a bank of BMSC products from healthy third party donors is described...
  8. pmc The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development
    Thomas Ichim
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 9:218. 2011
    ..These events signal the entrance of the field of stem cells into a new era: an era where hype and misinformation no longer triumph over economic and medical realities...
  9. pmc An immunologic portrait of cancer
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 9:146. 2011
    ..Here we reflect on commonalities and discrepancies among studies and on the genetic or somatic conditions that may cause this schism in cancer behavior...
  10. pmc Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy
    Cornelis J M Melief
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    J Transl Med 9:107. 2011
    ..This novel assembly will generate new ideas and new collaborations and possibly increase the rate of advancement of this field...
  11. pmc 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level
    Luciano Castiello
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 9:41. 2011
    ..Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is a growth factor widely used in immunotherapy both for in vivo and ex vivo applications, especially for its proliferative effects...
  12. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  13. pmc Let-7 microRNAs are developmentally regulated in circulating human erythroid cells
    Seung Jae Noh
    Molecular Medicine Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 7:98. 2009
    ....
  14. pmc Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation
    Jiaqiang Ren
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:1. 2007
    ..We will review islet transplantation, as well as the mechanisms underlying insulin transcription, translation and glucose stimulated insulin release...
  15. pmc Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer
    Hye Won Chung
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
    J Transl Med 7:38. 2009
    ..We investigated the correlation between the serum HMGB1 levels and the clinical and pathologic features of gastric cancer and evaluated the validity of HMGB1 as a potential biomarker for the early diagnosis of gastric cancer...
  16. pmc Gene expression profiling of cutaneous wound healing
    Kavita Deonarine
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:11. 2007
    ..Genome wide transcriptional analysis tools promise to further define the global picture of this complex progression of events...
  17. pmc CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects
    Stefanie L Slezak
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 5:17. 2007
    ..Adoptive immune and vaccine therapies have been used to prevent cytomegalovirus (CMV) disease in recipients of hematopoietic progenitor cell transplants, but the nature of T cell responses to CMV have not been completely characterized...
  18. pmc Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 6:39. 2008
    ..The HSCs were compared to peripheral blood leukocytes (PBLs) from 7 subjects...
  19. pmc Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 8:4. 2010
    ....
  20. pmc GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells
    Silvia Selleri
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 6:17. 2008
    ..Whether this secretion affects in an autocrine loop the CTLs themselves is unknown...
  21. pmc MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells
    Jiaqiang Ren
    Department of Transfusion Medicine, Clinical Center, National Institute of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    J Transl Med 7:20. 2009
    ..Non-coding microRNAs (miRNA) which regulate mRNA cleavage and inhibit encoded protein translation exhibit temporal or tissue-specific expression patterns and they play an important role in development timing...
  22. pmc Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model
    Hui Ling Yang
    Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China
    J Transl Med 7:22. 2009
    ..In this study, we observed that Caveolin-1(CAV1) expression can increase the cytotoxic and pro-apoptotic activity of RES in a dose- and time-dependent manner both in vitro and in vivo in a Hepatocellular Carcinoma animal model...
  23. pmc Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
    Andrea Worschech
    Genelux Corporation, San Diego Science Center, San Diego, California, USA
    BMC Genomics 10:301. 2009
    ..GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing their complete regression...
  24. pmc Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA
    BMC Cancer 11:451. 2011
    ....
  25. pmc Global transcriptional analysis for biomarker discovery and validation in cellular therapies
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Diagn Ther 13:181-93. 2009
    ..Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed...
  26. ncbi request reprint Cell processing: current status and future directions
    David Stroncek
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1184, USA
    Yonsei Med J 45:1-4. 2004
    ..The laboratory has also been preparing dendritic cells to support protocols using immune therapy to treat cancer. In addition, pancreatic islet cells are isolated from organ donors for transplantation to treat type I diabetes mellitus...
  27. pmc Potency analysis of cellular therapies: the emerging role of molecular assays
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:24. 2007
    ..Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and microRNA expression microarrays in potency testing of cellular therapies is discussed...
  28. pmc Developments in clinical cell therapy
    David Stroncek
    National Institutes of Health, Bethesda, Maryland, USA
    Cytotherapy 12:425-8. 2010
    ....
  29. ncbi request reprint Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Hematol 14:688-93. 2007
    ....
  30. ncbi request reprint Platelet transfusions
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Lancet 370:427-38. 2007
    ..We review commonly used platelet components, product modifications, transfusion practices, and adverse consequences of platelet transfusions...
  31. ncbi request reprint Advancing cancer biotherapy with proteomics
    David F Stroncek
    Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1148, USA
    J Immunother 28:183-92. 2005
    ..High-throughput proteomic technologies have now advanced to a stage where they have the potential to become effective discovery tools for biomarkers/predictors of disease, disease recurrence, and response to therapy...
  32. ncbi request reprint Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor
    David Stroncek
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 33:1109-17. 2005
    ..Proteomic analysis could improve our understanding of the mechanisms and consequences of myeloproliferation. Healthy subjects treated with granulocyte colony-stimulating factor (G-CSF) were used as a model of myeloproliferation...
  33. pmc Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions
    David F Stroncek
    Department of Transfusion Medicine and Clinical Center, NIH, Bethesda, Maryland 20892 1184, USA
    Transfusion 51:2647-55. 2011
    ..The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed...
  34. ncbi request reprint Pulmonary transfusion reactions
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1184, USA
    Semin Hematol 44:2-14. 2007
    ..Other blood donor, blood component, and transfusion recipient factors likely play a contributing or modulating role in pulmonary transfusion reactions, but prospective studies are needed to better understand their role...
  35. pmc Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a
    Stefanie Slezak
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 7:39. 2009
    ..disorders (MPDs) we compared molecular changes in neutrophils from patients with polycythemia vera (PV) and essential thrombocythosis (ET), to neutrophils stimulated by G-CSF administration and to normal unstimulated neutrophils..
  36. pmc Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients
    Kyoung Un Park
    Department of Transfusion Medicine, Clinical Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:945-55. 2010
    ..Although some expanded NK-cell product variability was observed, perhaps related to patient factors, further studies on larger numbers of products will be needed to determine the impact of these differences on clinical outcomes...
  37. ncbi request reprint Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Immunol 27:437-48. 2007
    ..This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs...
  38. pmc Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 121:2864-74. 2013
    ..These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens...
  39. pmc Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy
    Marianna Sabatino
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, MD, USA
    J Clin Oncol 27:2645-52. 2009
    ..High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified...
  40. ncbi request reprint CD177 polymorphisms: correlation between high-frequency single nucleotide polymorphisms and neutrophil surface protein expression
    Lorraine Caruccio
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Transfusion 44:77-82. 2004
    ..The purpose of this study was to determine if PRV-1 and NB1 are alleles of the same gene or two separate genes; and, moreover, if they are alleles, to explore potential correlations to NB1 glycoprotein expression...
  41. ncbi request reprint The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31
    Lorraine Caruccio
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 46:441-7. 2006
    ..PRV-1 mRNA is overexpressed by neutrophils from polycythemia vera patients and is homologous to NB1 a gene overexpressed in reactive neutrophilia...
  42. ncbi request reprint Factors affecting the formation of white particulate matter in red blood cell components
    Hina D Patel
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 45:1127-32. 2005
    ..Recently white particulate matter (WPM) in red blood cell (RBC) components has received increased attention. The nature and causes of WPM formation were investigated...
  43. ncbi request reprint Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone
    David F Stroncek
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 42:597-602. 2002
    ..The purpose of this study was to assess the kinetics of G-CSF plus dexamethasone neutrophil mobilization to determine whether the neutrophils can be mobilized and collected the same day...
  44. pmc Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures
    Robert E Donahue
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 114:2530-41. 2009
    ..Plerixafor-mobilized CD34(+) cells include more B-, T-, and mast cell precursors, whereas G-CSF-mobilized cells have more neutrophil and mononuclear phagocyte precursors...
  45. ncbi request reprint Neutrophil-specific antigen HNA-2a (NB1, CD177): serology, biochemistry, and molecular biology
    David Stroncek
    The Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Vox Sang 83:359-61. 2002
  46. ncbi request reprint Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration
    David F Stroncek
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 42:1466-72. 2002
    ..RBC components collected from donors with sickle cell trait frequently occlude WBC-reduction filters. In vitro, sickle trait RBCs have the potential for sickle Hb (Hb S) polymerization at low oxygen saturations and high Hb concentrations...
  47. ncbi request reprint Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration
    David F Stroncek
    Department of Tranfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 44:1293-9. 2004
    ..Techniques were investigated to successfully filter Hb AS donor blood by increasing the Hb oxygen saturation with storage bags and conditions suitable for transfusion products...
  48. pmc Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes
    Jong Baeck Lim
    Department of Transfusion Medicine, Warren G, Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 7:72. 2009
    ..To identify novel HLA-A*2402-restricted human cytomegalovirus (HCMV) immediate early-1 (IE-1) epitopes for adoptive immunotherapy, we explored 120 overlapping 15-amino acid spanning IE-1...
  49. ncbi request reprint Expression of human neutrophil antigen-2a (NB1) is increased in pregnancy
    Lorraine Caruccio
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 43:357-63. 2003
    ..This study investigated variations in neutrophil expression of HNA-2a by comparing the expression of epitopes recognized by three HNA-2a-specific CD177 antibodies among healthy adults and pregnant women...
  50. pmc 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity
    Carol Clayberger
    Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 188:6119-26. 2012
    ..Thus, the distinct functions of granulysin isoforms have major implications for diagnosis and potential new therapies for human disease...
  51. pmc Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians
    Xin Li
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:22. 2007
    ..In addition, we identified a putative haplotype rare in Tunisian patients with NPC that may serve as a genetic marker for further susceptibility studies...
  52. pmc Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness"
    Arun Balakumaran
    Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e11462. 2010
    ..This study confirms that SPION labeling does not alter the differentiation potential of the subset of stem cells within BMSCs...
  53. ncbi request reprint The use of bioinformatics to identify the genomic structure of the gene that encodes neutrophil antigen NB1, CD177
    Maria P Bettinotti
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, Bethesda, Maryland 20892 1184, USA
    Clin Immunol 102:138-44. 2002
    ..Most likely, NB1 and PRV-1 are alleles of the same gene, CD177, and the duplication of exons 4 through 9 is a pseudo gene...
  54. ncbi request reprint Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions
    Sara Deola
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunol 180:1362-72. 2008
    ..This observation provides a mechanistic explanation to previously reported experimental observations suggesting that B cells are required for T cell priming in vivo...
  55. pmc Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma
    Tae Hee Han
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunother 32:399-407. 2009
    ..There was no benefit of adding IL-1beta and TNF-alpha to LPS and IFN-gamma to produce mDCs...
  56. pmc HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients
    Ashok Nambiar
    Department of Transfusion Medicine, Bldg 10, 1C711, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:1680-7. 2006
    ..Triplet-matched transfusions were successful, regardless of CREG matching. Our data validate HLAMatchmaker for platelet transfusions and demonstrate its potential to refine and expand donor selection for HLA-alloimmunized patients...
  57. doi request reprint Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes
    Jeremy Pantin
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland Division of Hematology, Medical Oncology and BMT, Department of Medicine, Georgia Regents University, Georgia
    Am J Hematol 88:874-82. 2013
    ..Clinicaltrials.gov identifier: NCT00003838)...
  58. pmc Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions
    David F Stroncek
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Transfus Med Rev 21:273-86. 2007
    ....
  59. ncbi request reprint The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele
    Maurizio Provenzano
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 43:1567-74. 2003
    ..It was previously demonstrated that the CMV decamer (10-mer) peptide pp65(341-350), QYDPVAALFF, was able to induce CMV-specific CTLs in HLA-A*2402 CMV-seropositive individuals...
  60. ncbi request reprint Increasing oxygen tension improves filtration of sickle trait donor blood
    Karen M Byrne
    Department of Transfusion Medicine, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Warren G Magnuson Clinical Center, Building 10, Room 1C711, 10 Center Drive MSC 1184, Bethesda, MD 20892 2284, USA
    Br J Haematol 122:678-81. 2003
    ..Bags with added air had increased sO2 levels (from 49 +/- 10% to 76 +/- 6%). Filtration was successful for nine of 10 components with air, and one of 10 without air. Successful filtration of RBC components occurs when sO2 is increased...
  61. ncbi request reprint Leukoreduction filtration of whole-blood units from sickle trait donors: effects of a metered citrate anticoagulant system
    Barbara J Bryant
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 47:2233-41. 2007
    ..This study evaluates a blood collection instrument that adds citrate anticoagulant in a metered fashion, thus mitigating adverse citrate effects...
  62. ncbi request reprint Pasteurella multocida bacteremia in asymptomatic plateletpheresis donors: a tale of two cats
    Barbara J Bryant
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 47:1984-9. 2007
    ..Two cases of Pasteurella multocida bacteremia in asymptomatic plateletpheresis donors are reported. Clinical outcomes were profoundly different, emphasizing the importance of robust methods to detect bacterial contamination...
  63. pmc Analysis of a high-throughput HLA antibody screening assay for use with platelet donors
    Emmanuel Fadeyi
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD 20892, USA
    Transfusion 48:1174-9. 2008
    ..A high-throughput microbead-flow analyzer HLA antibody detection technique was compared with an enzyme-linked immunosorbent assay (ELISA) method...
  64. pmc Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils
    Barbara J Bryant
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 50:1203-9. 2010
    ..Efficient reduction of RBCs in granulocyte units would result in safe transfusion of RBC-incompatible units...
  65. ncbi request reprint Neutrophil alloantigens
    David Stroncek
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892 1184, USA
    Transfus Med Rev 16:67-75. 2002
    ..New polymorphisms in these antigen systems are still being described, but the complete understanding of these neutrophil antigen systems has been slow because of the complexity of these genes...
  66. ncbi request reprint G-CSF-induced spleen size changes in peripheral blood progenitor cell donors
    David Stroncek
    Department of Transfusion Medicine, National Institutes of Health, Warren G Magnuson Clinical Center, Building 10, Room 1C711, 10 Center Drive MSC 1184, Bethesda, MD 20892 1184, USA
    Transfusion 43:609-13. 2003
    ..This study evaluated the incidence and time course of splenic enlargement in PBPC concentrate donors and assessed factors affecting size changes...
  67. pmc Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells
    Jeong Won Shin
    Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 48:647-57. 2008
    ....
  68. pmc Molecular immune signatures of HIV-1 vaccines in human PBMCs
    Alessandro Monaco
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health Bethesda, MD, USA
    FEBS Lett 583:3004-8. 2009
    ..This ex vivo screening strategy represents an efficient tool for guiding modifications/optimizations of vaccination strategies and understanding failures in individuals enrolled in clinical trials...
  69. ncbi request reprint Detection of antibodies in acid eluates with the gel microcolumn assay
    Victoria A Greco
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, MD 20892, USA
    Transfusion 42:698-701. 2002
    ..DATs can also be performed with this system. The purpose of this study was to compare the gel microcolumn to the tube IAT using anti-IgG for the detection of antibodies eluted from RBCs...
  70. ncbi request reprint The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions
    Emmanuel A Fadeyi
    Department of Transfusion Medicine, Clinical Center, and the Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 47:545-50. 2007
    ..Antibodies to neutrophil-specific antigens are the best characterized cause of transfusion-related acute lung injury (TRALI)...
  71. ncbi request reprint Effects of storage time and exogenous protease inhibitors on plasma protein levels
    Saleh Ayache
    Immunogenetics Laboratory, Department of Transfusion Medicine, Warren G Magnuson Clinical Center National Institutes of Health, Bethesda, MD 20892 1184, USA
    Am J Clin Pathol 126:174-84. 2006
    ..The dramatic changes in protein levels during storage were independent of protease inhibitors and are likely due to cytokine production and/or release by leukocytes and platelets...
  72. pmc Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)
    Maurizio Provenzano
    Molecular Immunology Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 1:12. 2003
    ....
  73. ncbi request reprint KEL6 and KEL7 genotyping with sequence-specific primers
    Keli J Renoud
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 46:1510-4. 2006
    ..These SNPs distinguish the gene encoding Js(a), KEL6; and Js(b), KEL7...
  74. ncbi request reprint Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation
    Wesley T Stevens
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Transfusion 46:649-51. 2006
    ..Although identifying the cause of contamination is most often viewed in the context of recipient safety, this case illustrates the importance of a thorough evaluation on donor safety...
  75. doi request reprint Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses
    Fang Yin
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland, USA
    Stem Cells 32:1278-88. 2014
    ..However, BMSCs were ineffective in patients with prolonged GVHD with lower lymphocyte counts, which suggest that effective GVHD control by BMSCs requires a relatively intact immune system. Stem Cells 2014;32:1278-1288. ..
  76. doi request reprint Developing cellular therapies for retinal degenerative diseases
    Kapil Bharti
    Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland
    Invest Ophthalmol Vis Sci 55:1191-202. 2014
    ..Many of the ocular stem cell approaches we discuss are also being used more broadly, for nonocular conditions and therefore the model we develop here, using the precompetitive space, should benefit the entire scientific community. ..
  77. ncbi request reprint Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells
    Maurizio Provenzano
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 25:342-51. 2002
    ..As a result, this method measures naturally induced immune reactions...
  78. pmc Pilot analysis of cytokines levels in stored granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell concentrates
    Iyonna Woods
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 50:2011-5. 2010
    ..PBSC concentrates contain large numbers of white blood cells, and during storage the levels of soluble cytokines that could cause transfusion reactions may increase...
  79. pmc Another example of a KEL1 variant red cell phenotype due to a threonine to serine change at position 193 of Kell glycoprotein
    Hallie Lee-Stroka
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 48:925-9. 2008
    ..The molecular basis of this phenotype was investigated...
  80. ncbi request reprint The value of pH as a quality control indicator for apheresis platelets
    Cynthia Tudisco
    From the Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland
    Transfusion 45:773-8. 2005
    ..Standards and regulations require measurement of pH as an apheresis platelet (PLT) component quality monitor. The usefulness of this quality control (QC) measure was investigated...
  81. ncbi request reprint In vitro variables of red blood cell components collected by apheresis and frozen 6 and 14 days after collection
    Heather L Grose
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 46:1178-83. 2006
    ..This study evaluated in vitro variables of apheresis RBC stored for 6 and 14 days at 1 to 6 degrees C before glycerolization and 14 days after deglycerolization...
  82. pmc Antitumor vaccines, immunotherapy and the immunological constant of rejection
    Ena Wang
    National Institutes of Health, Department of Transfusion Medicine, Building 10, Room 1C711, Clinical Center, Bethesda, MD 20892, USA
    IDrugs 12:297-301. 2009
    ....
  83. ncbi request reprint Analysis of vaccine-induced T cells in humans with cancer
    Stefanie L Slezak
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Adv Exp Med Biol 684:178-88. 2010
    ..Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means ofeliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion...
  84. ncbi request reprint Spontaneous and treatment-induced cancer rejection in humans
    Ena Wang
    National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
    Expert Opin Biol Ther 8:337-49. 2008
    ..On the other hand, it is also well documented that on rare occasions tumors can be dramatically destroyed by the host's immune response...
  85. ncbi request reprint Improved gene transfer and normalized enzyme levels in primitive hematopoietic progenitors from patients with mucopolysaccharidosis type I using a bioreactor
    Dao Pan
    Gene Therapy Program, Department of Pediatrics, and Institute of Human Genetics, University of Minnesota, Minneapolis, MN, USA
    J Gene Med 6:1293-303. 2004
    ..Other inadequacies of current transduction protocols are related to their multi-step procedures, e.g., using tissue-culture flasks, roller bottles or gas-permeable bags for clinical application...
  86. ncbi request reprint Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals
    Maurizio Provenzano
    Immune Oncology Section, Department of Surgery, University Hospital ZLF, Hebelstrasse 20, 4031 Basel, Switzerland
    Cancer Immunol Immunother 56:1047-63. 2007
    ..We believe that the usefulness of these epitopes occurring naturally in non-cancer bearing patients as reagents for the immunization of patients with early or advanced stage NPC deserves further evaluation...
  87. ncbi request reprint MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts
    Maurizio Provenzano
    Institute for Surgical Research and Hospital Management, University of Basel, 4031 Basel, Switzerland
    Trends Mol Med 12:465-72. 2006
    ....
  88. pmc Sporadic leukoreduction filter failure during red blood cell component preparation: beware of rapid filtration
    Jeanne K Wang
    Transfusion 48:1766-7. 2008
  89. ncbi request reprint Heavy breathing in the blood bank: is it transfusion-related acute lung injury, our anxiety, or both?
    David F Stroncek
    Transfusion 47:559-62. 2007